CURRENT TRIALS

Research Study on Diarrhea in Patients with Irritable Bowel Syndrome
Patients with Irritable Bowel Syndrome (IBS) suffer from altered bowel function which frequently results in diarrhea. We are conducting a double-blind, placebo controlled research study to determine the efficacy and safety of an investigational drug (arverapamil) in the treatment of diarrhea-predominant IBS in both men and women. Participants in the study will receive study medication to be taken orally three times/day for 12 weeks. The study requires 5 visits during a 14-week period. These visits will included such procedures as physical exams, electrocardiograms (ECG's), and blood draws for laboratory tests. Participants are also required to complete daily diary entries.
PRESENTLY ENROLLING!

Eligibility criteria include:

Male or female, 18-75 years old

Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome

Willingness to complete a daily diary by telephone (5-10 minutes)

Participants CANNOT:

Have severe medical or surgical conditions

Have used antibiotic within one month of screening visit

Be taking any medications prohibited in the study by the Sponsor

Ulcer Risk with the Use of NSAID Pain Medication for Arthritis
About 43 million Americans suffer from arthritis, making it the number one cause of disability. Millions of Americans take medicine to fight chronic pain due to arthritis and other conditions. But some pain medicines may actually increase the risk for stomach ulcers. This research trial is studying an investigational medicine that may provide pain relief and reduce the risk of gastric ulcers. The 6-month study will include 4 endoscopies.
PRESENTLY ENROLLING!

Eligibility criteria include:

Constipation Related to Prescription Pain Medication
If you are taking a prescription pain medication like Vicodin®, Percocet®, or Oxycontin® and you are experiencing constipation or bloating you may be eligible for this research study. We are conducting a study to evaluate the efficacy and safety of an investigational drug in the treatment of bowel dysfunction related to prescription pain medication use. Participation will last up to 18 weeks, including screening, a 12-week treatment period and follow-up. Study visits will include physical exams, lab tests, and ECG's. Study drug will be taken twice daily by mouth. There will be no change in the participant's pain medication. Participants who complete this study may be eligible to enroll in a long-term (9-month), open-label extension study.
PRESENTLY ENROLLING!

Eligibility criteria include:

Gastroesophageal Reflux Disease (GERD)
Many people suffer from chronic heartburn or GERD. Symptoms of heartburn are typically caused by acid in the stomach flowing backward up into the esophagus (food tube running the length of the chest connecting the mouth to the stomach). Approximately 75% of people with GERD experience symptoms during the night. This research study will help determine if an investigational medicine can alleviate chronic nighttime heartburn or GERD symptoms.
PRESENTLY ENROLLING!

Eligibility criteria include:

Male or female 18-65 years of age

History of nighttime heartburn and GERD associated with sleep disturbance

History of erosive esophagitis more than 6 months prior to screening

Nighttime heartburn at least 3 of 7 nights each week

Willingness to have an endoscopy to evaluate the esophagus

Willingness to use an approved method of birth control (if required)

For further information please contact:
Arline Uhl, R.N.
(336) 286-1194
email: auhl@vitalresearchnc.com